Skip to content

Study · Animal study (in vivo) · 2010

3 results

GLP-1(7-36)-amide and Exendin-4 stimulate the HPA axis in rodents and humans.

Gil-Lozano M, Pérez-Tilve D, Alvarez-Crespo M, Martís A, Fernandez AM, Catalina PA, Gonzalez-Matias LC, Mallo F, Mallo F

Endocrinology2 Apr 2010Cited by 81 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rodents, exendin‑4 activated the HPA axis across administration routes and metabolic states, independently of glycemic and insulinotropic effects.

    In plain wordsIn rodents, exendin‑4 activated the hormone stress axis across administration routes and feeding states.

    Outcome
    IncreaseHPA axis activation
    Study

    n: not reported in source

    rodents
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · intracerebroventricular, iv, and ipAs given in this study.

    Source sentences

    Summary
    The effects of GLP-1/Ex-4 on the HPA axis are very consistent after distinct means of administration (intracerebroventricular, iv, and ip), irrespective of the metabolic state of the animals (fasting or fed ad libitum), and they were reproduced by different peptides in this family, independent of gl…
    1 context sentence
    Summary · context
    Here, we have studied the response of corticoadrenal steroids to the peripheral administration of GLP-1 (7-36)-amide and related peptides [exendin (Ex)-3, Ex-4, and Ex-4(3-39)] in rats, mice, and humans.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In diabetic rat and mouse models, the HPA effects attributed to GLP-1 and exendin‑4 were also observed.

    In plain wordsIn diabetic rats and mice, researchers also observed the stress hormone effects attributed to GLP-1 and exendin‑4.

    Outcome
    IncreaseHPA effects in diabetic animal models
    Study

    n: not reported in source

    DM-1 streptozotocin-rat or DM-2 muscle IGF-I receptor-lysine-arginine transgenic mouse models
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Indeed, these effects were also observed in diabetic subjects (DM-1 patients) and in the DM-1 streptozotocin-rat or DM-2 muscle IGF-I receptor-lysine-arginine transgenic mouse animal models.
    1 context sentence
    Summary · context
    The effects of GLP-1/Ex-4 on the HPA axis are very consistent after distinct means of administration (intracerebroventricular, iv, and ip), irrespective of the metabolic state of the animals (fasting or fed ad libitum), and they were reproduced by different peptides in this family, independent of gl…
  3. 03AnimalOther designMechanism

    In the mixed-species study, ACTH increased after exendin‑4 administration, without a species-specific attribution in the abstract.

    In plain wordsIn the mixed-species study, ACTH increased after exendin‑4. The abstract does not identify the species for this result.

    Outcome
    IncreaseACTH response
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mechanisms whereby circulating GLP-1 activates the HPA axis remain to be elucidated, although an increase in ACTH after Ex-4 and GLP-1 administration implicates the central nervous system or a direct effect on the pituitary.
    1 context sentence
    Summary · context
    Here, we have studied the response of corticoadrenal steroids to the peripheral administration of GLP-1 (7-36)-amide and related peptides [exendin (Ex)-3, Ex-4, and Ex-4(3-39)] in rats, mice, and humans.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.